依沙佐米产品是Ixazomib (MLN-2238), is a potent proteasome inhibitor (PI) with potential antineoplastic activity. MNL-2238 is a biologically active form of MLN9708. MLN-2238 has an improved pharmacodynamic profile and antitumor activity compared with bortezomib in both OCI-Ly10 and PHTX22L models.